Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Stivarga (CRC) Regorafenib Metastatic Colorectal Cancer Do not reimburse Complete
Stivarga (GIST) Regorafenib Gastrointestinal Stromal Tumour Reimburse with clinical criteria and/or conditions Complete
Stivarga Resubmission (CRC) Regorafenib Metastatic Colorectal Cancer Do not reimburse Complete
Strattera Atomoxetine hydrochloride Attention deficit hyperactivity disorder Do not list Complete
Strattera Atomoxetine hydrochloride Attention deficit hyperactivity disorder N/A Complete
Strensiq Asfotase alfa Hypophosphatasia, pediatric-onset List with criteria/condition Complete
Stribild Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir Disoproxil Fumarate HIV infection List with criteria/condition Complete
Sublinox Zolpidem tartrate Insomnia Do not list Complete
Sublocade buprenorphine Opioid use disorder, treatment Reimburse with clinical criteria and/or conditions Complete
Suboxone Buprenorphine/naloxone Opioid drug dependence (Substitution treatment) List with clinical criteria and/or conditions Complete